Genelux (GNLX) Research & Development (2022 - 2026)
Genelux (GNLX) posted quarterly Research & Development of $5.8 million for Q1 2026, up 22.99% year-over-year from $4.7 million in Q1 2025, and up 2.19% quarter-over-quarter from $5.7 million in Q4 2025.
Genelux (GNLX) Research & Development (2022 - 2026) Analysis & Trends
Genelux's Research & Development history runs 5 years deep, the most recent figure standing at $5.8 million for Q1 2026.
- In Q1 2026, Research & Development rose 22.99% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $20.9 million (up 6.32% YoY), while the FY2025 annual figure was $19.9 million, up 4.49% from the prior year.
- Research & Development for Q1 2026 stood at $5.8 million, up from $5.7 million in the prior quarter.
- The five-year high for Research & Development was $6.5 million in Q4 2024, with the low at $2.4 million in Q3 2022.
- The 5-year median for Research & Development is $4.2 million (2023), against an average of $4.2 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 68.56% in 2023, then fell 13.28% in 2025.
- Genelux's Research & Development stood at $2.5 million in 2022, then surged by 68.56% to $4.2 million in 2023, then surged by 56.73% to $6.5 million in 2024, then dropped by 13.28% to $5.7 million in 2025, then rose by 2.19% to $5.8 million in 2026.
- Business Quant data shows GNLX's Research & Development at $5.8 million in Q1 2026, $5.7 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | 5.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.78 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 4.76 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 6.52 Mn |
| Sep 30, 2024 | 4.05 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 4.01 Mn |
| Dec 31, 2023 | 4.16 Mn |
| Sep 30, 2023 | 2.82 Mn |
| Jun 30, 2023 | 2.94 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 2.47 Mn |
| Sep 30, 2022 | 2.41 Mn |